G1SK34 logo

GSK BOVESPA:G1SK34 Stock Report

Last Price

R$41.96

Market Cap

R$424.3b

7D

0.5%

1Y

17.3%

Updated

25 Dec, 2024

Data

Company Financials +

G1SK34 Stock Overview

Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details

G1SK34 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

GSK plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for GSK
Historical stock prices
Current Share PriceUK£41.96
52 Week HighUK£50.15
52 Week LowUK£36.48
Beta0.33
1 Month Change5.56%
3 Month Change-5.83%
1 Year Change17.34%
3 Year Changen/a
5 Year Changen/a
Change since IPO26.88%

Recent News & Updates

Recent updates

Shareholder Returns

G1SK34BR PharmaceuticalsBR Market
7D0.5%4.3%-0.8%
1Y17.3%-26.1%-13.7%

Return vs Industry: G1SK34 exceeded the BR Pharmaceuticals industry which returned -25.3% over the past year.

Return vs Market: G1SK34 exceeded the BR Market which returned -13% over the past year.

Price Volatility

Is G1SK34's price volatile compared to industry and market?
G1SK34 volatility
G1SK34 Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement5.0%
10% most volatile stocks in BR Market9.6%
10% least volatile stocks in BR Market2.9%

Stable Share Price: G1SK34 has not had significant price volatility in the past 3 months compared to the BR market.

Volatility Over Time: G1SK34's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
171570,212Emma Walmsleywww.gsk.com

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

GSK plc Fundamentals Summary

How do GSK's earnings and revenue compare to its market cap?
G1SK34 fundamental statistics
Market capR$424.30b
Earnings (TTM)R$19.49b
Revenue (TTM)R$243.06b

21.8x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
G1SK34 income statement (TTM)
RevenueUK£31.31b
Cost of RevenueUK£8.65b
Gross ProfitUK£22.67b
Other ExpensesUK£20.15b
EarningsUK£2.51b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.62
Gross Margin72.39%
Net Profit Margin8.02%
Debt/Equity Ratio119.4%

How did G1SK34 perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

99%

Payout Ratio

Does G1SK34 pay a reliable dividends?

See G1SK34 dividend history and benchmarks
When do you need to buy G1SK34 by to receive an upcoming dividend?
GSK dividend dates
Ex Dividend DateNov 13 2024
Dividend Pay DateJan 15 2025
Days until Ex dividend43 days
Days until Dividend pay date20 days

Does G1SK34 pay a reliable dividends?

See G1SK34 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:37
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GSK plc is covered by 62 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research